Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

Molecules. 2022 Jan 30;27(3):948. doi: 10.3390/molecules27030948.

Abstract

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide. Numerous drugs have been developed to treat lung cancer patients in recent years, whereas most of these drugs have undesirable adverse effects due to nonspecific distribution in the body. To address this problem, stimuli-responsive drug delivery systems are imparted with unique characteristics and specifically deliver loaded drugs at lung cancer tissues on the basis of internal tumor microenvironment or external stimuli. This review summarized recent studies focusing on the smart carriers that could respond to light, ultrasound, pH, or enzyme, and provided a promising strategy for lung cancer therapy.

Keywords: drug delivery; lung cancer; stimuli-responsive.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Delayed-Action Preparations / pharmacology*
  • Drug Carriers / chemistry*
  • Drug Delivery Systems*
  • Humans
  • Hydrogen-Ion Concentration
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy*
  • Smart Materials / pharmacology*

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Drug Carriers
  • Smart Materials